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Reduction in the use of animals in Toxicology is an important goal despite the continued need to 
assess drug and chemical safety in man.  However, a limitation to in vitro screening for drug and 
chemical toxicity is the lack of available human hepatocytes and the difficulties associated with 
generating fully functional hepatocytes from stem cells. Previously, we have shown that a rat 
pancreatic acinar cell line is capable of trans-differntiating into fully functional hepatocyte-like cells 
in response to glucocorticoid via a serine/threonine protein kinase mechanism alone. Here we 
demonstrated that differentiation only occurs with glucocorticoids, not other steroids.  We also 
investigated the potential of human pancreatic cells to undergo the same process.  Analysis of adult 
human pancreata at the level of mRNA, protein and by immunohistochemical staining demonstrated 
that long term systemic exposure to glucocorticoid therapy resulted in differentiation of exocrine 
tissue to hepatocyte-like tissue.   Glucocorticoid treatment of human pancreatic acinar cells in 
culture also resulted in trans-differentiation to hepatocyte-like cells.  Both in vivo and in vitro, trans-
differentiation of pancreas cells to hepatocytes was associated with an induction of SGK1 variant 
transcripts that have been previously shown to drive B-13 differentiation to hepatocytes.  Adult 
exocrine human pancreas therefore responds in a similar qualitative fashion to that previously 
observed in rodents exposed to elevated glucocorticoid – that of a differentiation into hepatocyte-
like cells.  Understanding the enhanced response of B-13 cells to glucocorticoid and engineering 
this response in a replicating human acinar cell could generate an unlimited supply of functional 
human hepatocytes in vitro that could be useful in a variety of applications, including screening 
drugs and chemicals for hepatic metabolism and toxicity.  
 
Key words: acinar, B-13, glucocorticoid, stem, trans-differentiation. 
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Introduction 
The B-13 rat pancreatic cell line is an expandable progenitor-like cell with the capacity to generate 
an unlimited supply of functional rat hepatocyte-like cells (termed B-13/H cells) in vitro, without 
the need for animal donors.1-6  The cell line appears to be unique in that it differentiates into B-13/H 
cells that are both qualitatively and quantitatively comparable to freshly isolated hepatocytes.1-6  
Furthermore, B-13 cells undergo a change to B-13/H cells in response to the addition of a single 
glucocorticoid hormone, providing a simple and highly reproducible system for hepatocyte 
generation.6  In contrast to primary hepatocytes, B-13/H cells remain differentiated for many weeks 
on plastic substrata, whereas primary hepatocytes rapidly de-differentiate.6  This latter quality could 
make B-13/H cells a valuable model for studying hepatic metabolism and toxicity in vitro, since 
they offer a stable phenotype for studying toxic processes which may take long periods of time to 
manifest their effects (e.g. low level chronic exposure effects, carcinogenesis). 
We have spent the last few years both defining the mechanisms that regulate the 
differentiation process and putting the B-13 response to glucocorticoid into a physiological context.  
We sought to investigate whether the trans-differentiation of acinar cells to hepatocytes is a 
physiologically feasible outcome in normal cells, both in vitro and in vivo.  In a series of papers, we 
have shown that the B-13 to B-13/H trans-differentiation is regulated by Wnt signalling and 
serine/threonine protein kinase (SGK1) induction4,5 and is related to a pathophysiological response 
of the rodent pancreas to glucocorticoid.7,8  B-13 cells appear to be hyper-responsive to 
glucocorticoid with respect to hepatic differentiation, but the response occurs in normal rodent 
pancreas acinar cells as a result of physiologically abnormally high concentrations of 
glucocorticoid, both in vitro and in vivo.6  It has yet to be established precisely why pancreatic 
acinar cells should specifically trans-differentiate into hepatocytes in response to glucocorticoid (in 
contrast to other tissues which are relatively unaffected).  However, it is likely associated with the 
acinar cell’s propensity to revert to a proliferative embryonic ductal phenotype (as seen in vitro9,10; 
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the close developmental relationship between liver and pancreas11 and the promotion of tissue 
maturation by glucocorticoids6. 
 Since a long term aim of this program of research is to isolate (or engineer) a human 
equivalent of the B-13 cell, we examined whether the B-13 response to dexamethasone (DEX) - a 
synthetic glucocorticoid - is specific to glucocorticoids or whether the response occurs to other 
steroids.  In addition, we sought evidence that an hepatocyte phenotype occurs in human pancreatic 
cells in vivo and in vitro. 
We show that B-13 cells differentiate into B-13/H cells in response to several 
glucocorticoids but not to a range of other steroid classes.  We also demonstrate that long term 
treatment with glucocorticoid in man results in liver levels of expression of hepatocyte markers in 
the human pancreas, and that culturing human acinar cells with glucocorticoid also results in 
expression of genes specific to hepatocytes.  These changes were associated with an induction in 
SGK1 variant gene expression and suggest a human B-13 equivalent is a realistic prospect if the 
glucocorticoid hyper-responsive mechanism in B-13 cells can be replicated in human cells.  
Fairhall  et al   In vitro hepatocyte generation 
 
6 
Results 
 
The trans-differentiation of B-13 cells to B-13/H cells is a specific response to glucocorticoid 
steroids. 
The trans-differentiation of pancreatic B-13 cells to hepatocyte-like B-13/H cells in response 
to dexamethasone includes a change in morphology (Figure 1A) and expression of liver-specific 
mRNAs (cytochrome P450 2E1 [CYP2E1] and carbamoyl phosphate synthase [CPSI]) from 
undetectable levels as determined by RT-PCR (Figure 1B).  However, expression of the pancreatic 
acinar cell marker amylase was retained in B-13/H cells (Figure 1B), as previously reported.1,2   
To establish whether trans-differentiation is a response that can occur on exposure to other 
steroids, the B-13 cell was screened for its response to a range of glucocorticoids and other steroids.  
Figure 1C demonstrates that B-13 cells responded to the endogenous rat glucocorticoid 
corticosterone at both normal endogenous (300nM)12 and elevated Cushing’s disease levels 
(1.5μM)8 as well as to a range other synthetic clinically-employed glucocorticoids: prednisolone, 
DEX and betamethasone (Figure 1C).  In contrast, no other steroids or nuclear receptor activators 
directed the B-13 cells to a B-13/H phenotype (data not shown) or induced the expression of 
hepatocyte genes (Figure 1C).   Figure 1C also indicates that B-13/H cells express similar levels of 
CYP2E1 and CPSI as freshly isolated rat hepatocytes, confirming their quantitative comparability 
to normal liver hepatocytes in terms of expression levels. 
Immunocytochemical staining confirmed that cells B-13/H cells retained expression of both 
amylase and CYP2E1 and that it was not a sub-set of cells within the culture expressing CYP2E1 
only (Figure 1D).  These data indicate that the appearance of B-13/H cells in vitro is a specific 
response to glucocorticoids that does not occur in response to other steroids or ligands of other 
closely-related nuclear receptors, and that B-13/H appearance is dependent on trans-differentiation 
from acinar cells. 
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Adult Human Acinar Cells Express Hepatocyte Markers In Vivo and In Vitro in Response to 
Glucocorticoid Exposure. 
Previous work has shown that markers of liver gene expression appear in rodent pancreata13-
16 and human fetal acinar cells.17  To establish whether adult human pancreatic tissue is similarly 
plastic in vivo and responsive to glucocorticoid, tissue from a patient treated for at least 20 years 
with systemic glucocorticoid (NP10) was compared to tissue from patients with no history of long 
term systemic glucocorticoid therapy (Figure 2).  Figure 2A demonstrates that 3 mRNA transcript 
markers expressed at high levels in hepatocytes (cytochrome P450 - CYP3A4) or specifically in 
hepatocytes (carbamyl phosphate synthase [CPSI] and albumin) were readily detectable in tissue 
from patient NP-10, but were undetectable in 4 control pancreas samples (patients with no history 
of systemic glucocorticoid therapy).  Examination at the protein level using Western blotting 
confirmed expression of liver proteins in the NP10 pancreas, and indicate that the levels of 
expression are similar to that observed in human liver (Figure 2B).  Immunohistochemical analyses 
confirmed that hepatocyte gene expression was present in the acinar regions of the NP10 pancreas 
(Figure 2C).  These data confirm the observations made on archived pancreatic tissue isolated from 
2 other patients maintained on systemic glucocorticoid (Figure 3). 
Previous work has identified that SGK1 is markedly up-regulated in B-13 cells when treated 
with glucocorticoid, most notably an alternatively transcribed variant 3 (also termed variant C).4  
Transfecting B-13 cells with expression vectors encoding the different human SGK1 variants 
demonstrated that SGK1 v3 (and an unassigned human-specific F variant) directed B-13 cells into 
hepatocytes without glucocorticoid treatment, demonstrating a pivotal role for specific SGK1 
transcript induction in the trans-differentiation response.4  Figure 2D demonstrates that transcripts 
for SGK1 v3 and SGK1 variant F were detectable in NP08 and NP10 pancreata, with the highest 
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expression in NP10 (the patient maintained long term on systemic glucocorticoid and showing 
extensive evidence of hepatocyte gene expression in their pancreas at resection).   
 To establish whether adult human pancreatic acinar cells are capable of trans-differentiation 
to hepatocyte-like cells in vitro, acinar cells were isolated and cultured with or without the addition 
of 10µM dexamethasone (DEX), a synthetic glucocorticoid.  Figure 4A indicates that cells from 
patient NP8 expressed a range of hepatic markers at the mRNA level (CYP2E1, CPSI, albumin, 
CYP3A4) in response to DEX treatment, with no expression detected in cells cultured in basal 
media.  Cells from patient NP10 – which already expressed hepatic markers – retained the 
expression of the hepatic markers when cultured with DEX, except for albumin mRNA.  CYP1A1 
mRNA, which was not induced in NP08 cells by DEX, was induced from undetectable levels by 
DEX in NP10 cells (Figure 4A).  Figure 4B demonstrates that cultured human acinar cells retained 
the expression of amylase and that treatment with DEX resulted in the co-expression of CYP2E1 
and amylase as previously observed with B-13 cells.1-4  Thus, DEX treatment likely results in the 
trans-differentiation of acinar cells to hepatocyte-like cells, rather than hepatic differentiation of a 
progenitor cell present within the culture.   Furthermore, whereas acinar cells became more 
fibroblastic in morphology with time in culture, the addition of DEX promoted a more epithelial 
morphology.  Figure 4C shows the levels of expression of SGK1 variants after culture for 14 days 
with or without the addition of glucocorticoid.  DEX treatment induced all SGK1 variants in cells 
isolated from patient NP08 (which trans-differentiated into hepatocytes in response to DEX), 
whereas cells from patient NP09 (which trans-differentiated into hepatocytes in response to DEX 
with low efficiency – data not shown) only showed induction of SGK1 v1 transcript and no 
expression at any time of SGK1 v3 and F (Figure 4C).   Acinar cells from patient NP10 (which 
already contained hepatocytes due to prolonged therapy with glucocorticoid) showed retained or 
further induction of SGK1 variant transcripts with DEX treatment (Figure 4C).   
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Discussion 
 
The data in this paper demonstrate for the first time that hepatocyte-like cells appear in the 
adult human pancreas in response to prolonged glucocorticoid exposure.  Thus, the patho-
physiological response of this tissue to glucocorticoid in rodents (and the mechanisms which 
regulate it), also exists in man.  It is therefore reasonable to predict that if the changes that have 
occurred in B-13 cells can be replicated in a human pancreatic acinar cell, they will behave 
similarly to B-13 cells.  Such a resource would have extensive utility in a range of toxicity 
investigations. 
An intriguing question is why hepatocyte-like cells appear in the pancreas in response to 
excessive glucocorticoid exposure?  In addition to their role in playing a regulatory role in 
metabolism, glucocorticoids have an important role in cellular differentiation.  Glucocorticoid 
levels are low in the developing fetus because placental 11β hydroxysteroid dehydrogenase 2 
inactivates maternal glucocorticoid.18  In humans and many animal species, there is a rise in 
glucocorticoid concentrations during late pregnancy that parallels the increased maturity of fetal 
organs.19  The importance of glucocorticoids in development is clearly illustrated in the lung, where 
therapeutic use reduces the incidence of respiratory distress in premature birth.20,21  It is likely 
therefore, that normal glucocorticoid concentrations promote the maturation of tissues toward a 
neonatal phenotype.  This is supported by empirical observations with stem cell differentiation to 
mature cell types and has resulted in glucocorticoid frequently being incorporated into media 
designed to promote differentiation to mature phenotypes.22-26   Since pancreatic tissue is a default 
state of differentiation for embryonic pancreatic cells capable of being directed toward an hepatic 
phenotype,27 it is likely that the mechanism(s) which promotes this process remains functional in 
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adult cells and/or may modulate differentiation when normal adult cells are exposed to high levels 
of glucocorticoid. 
Recent data from this laboratory has shown that B-13 cells have a number of chromosomal 
changes (but retain a 4n complement of chromosomes),28 a feature typical of many dividing cells 
that have been propagated for some time in vitro but not undergone transformation, such as 
embryonic stem cell lines.29  However, B-13 do not grow in soft agar or form tumours in 
NOD/SCID mice, indicating that they retain a requirement for anchorage-dependent growth and 
responsiveness to factors which prevent un-controlled cell growth.28   Interestingly, B-13 cells only 
engraft in to the liver and pancreas.28   
The importance of understanding the genetic changes that have occurred in the B-13 cells as 
well as the mechanisms that control differentiation lies in the fact that a human equivalent would 
have extensive basic research and clinical value.  Human hepatocytes are a scarce resource and a 
human B-13 equivalent would provide a plentiful supply of functional cells to be generated in vitro.  
Also, because the B-13 progenitor cell is proliferative, recombinant DNA technologies can be 
applied to manipulate the cells and to generate hepatocytes with genetic alterations.  Hepatocytes 
are a valuable resource for screening drugs and chemical metabolism and toxicity.6  Stably 
transfecting variant drug metabolizing enzyme or drug transporter genes in human B-13 cell lines 
would significantly advance testing for drug and chemical metabolism and toxicity in man.   
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Materials and methods 
 
Human Tissues 
Human liver and pancreas tissue was obtained with patient consent and with approval of the 
Newcastle & North Tyneside 2 Research Ethics Committee and the Wales Research Ethics 
Committee respectively (see Table 1 for patient details).  Human liver tissue was prepared from the 
margins of tissue removed from patients having a resection for both benign and malignant tumours. 
 
RT-PCR.  
Total RNA was purified using Trizol (Invitrogen, Paisley, UK) and RT-PCR performed and 
analysed essentially as previously outlined.7  Primer sequences are given in Table 2.  Primer 
sequences for the amplification of rat sequences have been published previously.7  
 
Western blotting. 
Western blotting was performed essentially as previously outlined30 with antibodies described 
previously.6-8  Detection was achieved using an ECL kit (Amersham, UK). 
 
Immunohistochemistry. 
Tissues were fixed in formalin and processed for immunohistochemistry as previously outlined with 
antigen retrieval using 0.01M citrate buffer.30  Tissue sections were then incubated with 3% H2O2 
for 10 minutes at room temperature (RT) to quench endogenous peroxide activity, and then washed 
for 5 minutes in 1 x PBS.  Cultured cells were prepared by permeabilising in ice cooled methanol 
for 10 minutes before washing in 1xPBS and fixing in 2% w/v formaldehyde and 0.2% 
gluteradehyde in 1xPBS pH 7.4.  Non-specific binding of antibodies was blocked in all samples 
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through incubation with 20% (v/v) bovine foetal calf serum (FCS) in 1xPBS for 20 minutes at room 
temperature.  Samples were then incubated with primary antibodies diluted in 0.05% (v/v) FCS; 
anti-CYP2E1 (Abcam - ab28146 1:200 dilution); anti-amylase (Santa-Cruz - SC12821 1:300 
dilution), and left to incubate overnight at 4°C. Samples were washed twice in 1xPBS before 
applying secondary antibodies for 1 hour at RT - alkaline phosphatase conjugated donkey 
polyclonal anti-rabbit IgG (Abcam - ab97061) and peroxidise conjugated rabbit anti-goat IgG 
(Sigma - A5420) both at a 1:200 dilution. Samples were washed twice in 1xPBS before colour 
development was carried out using BCIP®/NBT substrate system followed by Liquid DAB+ 
substrate chromogen system for CYP2E1 (alkaline peroxidase  activity) and Amylase (HRP 
activity) expression respectively.  In all cases control sections were stained without primary 
antibody incubation for each individual antibody used. After colour development slides were rinsed 
briefly in H2O and counterstained using nuclear fast red (Vector laboratories) when required. 
Samples were sequentially dehydrated through 50%, 75%, 95%, 100% ethanol and finally into 
xylene before mounting in depex™. 
 
Cell Isolation and Culture. 
Acinar cells were obtained as by-products of human islet isolation as described previously31 with 
minor modification. Briefly, human pancreas was distended with a freshly prepared solution 
consisting of ~2000 units of collagenases NB1 (Serva, Germany) and 0.15mg/ml Pefabloc SC Plus 
serine protease inhibitor (Roche, Germany) and followed up with ~25 units of neutral protease NB 
(Serva, Heidelberg, Germany). The pancreas was then digested at 37oC. Human islets were purified 
using a cooling COBE 2991 machine. The remaining enriched exocrine tissues were retrieved and 
washed by re-suspending in MEM solution centrifuged at 1000rpm in a bench top centrifuge for 1 
min. The supernatant was discarded and the cells washed a further two times.  The cells where then 
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cultured in Dulbecco’s minimum essential medium supplemented with 10% (v/v) fetal calf serum, 
80u/ml penicillin and 80µg/ml streptomycin. 
Rat and human hepatocytes were prepared by collagenase perfusion essentially as 
previously described.30  B-13 cells were routinely cultured in Dulbecco’s minimum essential 
medium supplemented with 10% (v/v) FCS, 80u/ml penicillin and 80µg/ml streptomycin.  All cells 
were incubated at 37oC in an humidified incubator gassed with 5% CO2 in air.   Steroids and other 
compounds were all purchased from the Sigma Chem Co. (Poole, UK) and were added to medium 
from 1000-fold concentrated ethanol vehicle solvated stocks, control cells were treated with 0.1% 
(v/v) ethanol alone as control.   
 
 
  
Supported by in part by a Medical Research Council ITTP PhD studentship to EAF 
and by European Commission FP7 program grant 'D-Liver' (EC Contract No. 
287596; http:// www.D-LIVER.eu/). 
. 
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Figure legends. 
 
Figure 1.  The model B-13 rat pancreatic acinar cell line trans-differentiates into hepatocytes 
in response to glucocorticoid treatments but not in response to other steroids or nuclear 
receptor agonists.  A, typical light micrographs of parent B-13 cell line (upper) and B-13/H cells 
(lower) observed after 14 days treatment with 10nM DEX.  B, RT-PCR analysis for the indicated 
transcript.  PCR con, amplification reaction in the absence of input RNA during the reverse 
transcription step.  C, Western blot for the indicated protein after treatment with the indicated 
concentration of glucocorticoids or other compounds for 14 days.  Note, that trans-differentiation to 
B-13/H cells results in a block in mitosis (and these cells remain viable for at least 60 days in this 
state.2-4  In the absence of trans-differentiation, B-13 cells require sub-culture to prevent cell death 
and so cells treated with other compounds required sub-culturing.  The normal endogenous 
concentrations in rats were used when greater than 10nM, to compare with dexamethasone.  For the 
non-glucocorticoids the rat serum levels are reported to be: progesterone, 250nM in pregnancy;32 
17β-estradiol, 40pM;32 dihydrotestosterone and testosterone, <15-30nM, based on the concentration 
of testosterone;33 aldosterone, 0.2 nM34 1,25 dihydroxyvitamin D, based on circulating 25 
hydroxyvitamin D of 80nM in humans35 and thyroxine, 10nM.36  These approx. concentrations 
were used or increased to 10nM to avoid false negative results.  D, immunohistochemical staining 
for CYP2E1 and/or amylase.  No 1o Ab, staining under identical conditions without the addition of 
primary antibodies.  All data typical of at least 10 separate experiments. 
 
 
Figure 2.  Screening human pancreas samples for the expression of hepatic markers.  A, RT-
PCR for the indicated transcript.  PCR control, amplification in the absence of RNA in the 1st strand 
cDNA synthesis step.  B, Western blot for the indicated protein.  C, Immunohistochemical staining 
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for CYP3A4 in sections from control human liver and pancreas and in pancreas sections from 
NP10, no primary control – identical staining without primary antibody incubation (see Supp Figure 
1). 
 
Figure 3. Immunohistochemical staining of human pancreas and liver sections.  A, Sections 
were stained for the exocrine pancreas marker amylase or liver markers CYP2E1 and CPS-I.  
Control pancreas was obtained from a patient with no record of extended systemic glucocorticoid 
therapy and no overt pancreatic abnormalities in H and E-stained sections.  Two human pancreas 
samples from patients (HP1 and HP2) maintained on systemic glucocorticoid were available as 
archived paraffin blocks only.  HP1 was a 65 year old male that had been maintained on 
prednisolone for 8 months for the treatment of pemphigoid.  The patient underwent a 
pancreaticoduodenectomy for a pancreatic adenocarcinoma.  HP2 was a 35 year old female 
recipient who received a simultaneous pancreas kidney transplant for end stage diabetic 
nephropathy. Her immunosuppressive regimen included prednisolone. Approximately 1 year after 
implantation the pancreas had to be removed because of sepsis and pancreas graft 
rejection/thrombosis.  Liver sections were prepared from normal tissue at the margins of an 
hepatectomy for a secondary tumour.  Mild steatosis observed is common. B, Further high powered 
fields from HP2 immunostained for CYP2E1, demonstrating positive staining in both acinar and 
ductal cells.  In general, positive cells were observed in acinar regions in occasionally in duct cells.  
Similar results were observed in sections from HP1, data not included. 
 
Figure 4.  Human pancreatic acinar cells in culture express hepatocyte marker genes in 
response to treatment with glucocorticoid – trans-differentiation correlates with SGK1 v3 and 
F induction.  Human pancreatic acinar cells were isolated as outlined in the methods section and 
where indicated, treated with 10μM dexamethasone (DEX) or ethanol vehicle as control.  After 14 
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days, cells were harvested and analyzed.  A, RT-PCR for the indicated transcript.  PCR control, 
amplification in the absence of RNA in the 1st strand cDNA synthesis step. B,  
Immunohistochemical staining for amylase and CYP2E1 in human acinar cells cultured in control 
medium or medium supplemented with 10µM DEX for 14 days.  Cells were fixed and co-stained 
amylase (brown) and CYP2E1 (blue) – data typical of staining from cells isolated from 5 
individuals. C, RT-PCR for SGK1 variant transcript expression in human acinar cells treated for 14 
days with (+) or without (-) 10µM DEX for 14 days. 
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Table 1.  Details of fresh human pancreas samples used in this research. 
 
Patient 
code 
Age / Sex Disease status 
   
NP06 78 / ♂ Pancreaticoduodectomy for an ampullary adenocarcinoma.  
Pancreatic parenchyma demonstrated mild focal atrophy but 
no evidence of chronic pancreatitis.  No history of systemic 
glucocorticoid therapy. 
 
NP07 47 / ♀ Pancreaticoduodectomy for distal cholangiocarcinoma.  
Pancreatic parenchyma lobular structure preserved with 
patchy atrophy, fibrosis and inflammation consistent with 
obstructive pancreatitis.  Islets of Langerhans appear normal.  
No history of systemic glucocorticoid therapy. 
 
NP08 52 / ♂ Pancreaticoduodectomy for a pancreatic ductal 
adenocarcinoma.  Background pancreatic parenchyma 
preserved with a normal lobular architecture.  Islets of 
Langerhans appear normal. No history of systemic 
glucocorticoid therapy. 
 
NP09 75 / ♂ Pancreaticoduodectomy and liver resection for a gall bladder 
adenocarcinoma.  Pancreatic parenchyma shows normal 
lobular architecture with no metaplastic or dysplastic changes 
in the pancreatic ducts.  Islets of Langerhans show normal 
distribution and size.  No history of systemic glucocorticoid 
therapy. 
 
NP10 87 / ♀ Distal pancreatectomy, splenectomy and nephrectomy for 
ductal adenocarcinoma of the tail of the pancreas.  
Background parenchyma shows pancreatic atrophy, patchy 
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chronic inflammation.  Patient had diabetes and polymyalgia 
rheumatica.  Received prednisolone therapy for at least 20 
years. 
   
 
Tissue at the margins of the resection with a normal macroscopic appearance, and as far away from 
the tumor as possible, were sampled in these studies.  For pathology archived block samples - HP1 
and HP2 – which were only available as fixed tissue – see figure 3 legend. 
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Table 2. DNA oligonucleotide sequences employed in RT-PCR amplification. 
 
 
Oligo ID 
 
5'-3' sequence 
An’ling 
conditions 
(oC) 
 
 
Comments 
    
RT-PCR 
 
   
hCYP2E1US TCCTTCACCCGGTTGGCCCA 58 Will amplify human CYP2E1  (NM_000773.3) cDNA 
sequence of 93bp. hCYP2E1DS 
 
CACCGCCTTGTAGCCGTGCA  
hCYP3A4US ACGGGACTATTTCCACCACCCCC 56 Will amplify human CYP3A4 (NM_017460.3) cDNA 
sequence of 322bp. hCYP3A4DS 
 
CTGACAAAGGCCCCACGCCAA  
hCYP1A1US TTCCCTGATCCTTGTGATCCCAGGC  Will amplify human CYP1A1 (NM_000499.3) cDNA 
sequence of 781bp. hCYP1A1DS 
 
AGAGCCAACCACCTCCCCGAA 56 
hC/EBPβUS CCAGCCACCAGCCCCCTCACTAATA 58 Will amplify human CAAT/EBPβ (NM_005194.2) cDNA 
sequence of 264bp. hC/EBPβDS 
 
CCAAGCAGTCCGCCTCGTAGT  
hALBUMINUS AGCTGCCTGCCTGTTGCCAAA 56 Will amplify human albumin (NM_000477.5) cDNA 
sequence of 135bp. hALBUMINDS 
 
AGGCGAGCTACTGCCCATGC  
hCPSIUS TTTAGCCGAGGCCCATGCCACA 58 Will amplify human CPSI variant 1 (NM_001122633.1) 
cDNA sequence of 238bp.  US primer does not hybridise 
to variant 2 (NM_001875.3) 
 
hCPSIDS 
 
CCAGCAACAGAGGATGGATGGCC  
hAMYLASEUS ACATGGGGCTGGAGGAGCCT 55 Will amplify human amylase - alpha 2A (NM_000699.2)  
and human amylase alpha 2B (NM_020978.3)  cDNAs  
sequences of 170 and 172bp respectively. 
 
hAMYLASEDS TGGTGGCCCAACCCAATCAT  
   
   
rmhGAPDHUS TGACATCAAGAAGGTGGTGAAG  50 Will amplify  rat (NM_017008),  human (NM_002046) or  
mouse (NM_008084)  glyceraldehyde 3 phosphate 
dehydrogenase cDNA sequence of 243bp. 
 
rmhGAPDHUS TGACATCAAGAAGGTGGTGAAG   
hSGK1v1US CGAGCCGGTCTTTGAGCGCTAAC 55 Will amplify human SGK1 variant 1 (NM_005627.3) 
cDNA sequence of 118bp.  Also referred to as SGK1A 
and wild type sequence. 
 
hSGK1v1DS GAATTGCCACCATGCCCCTCATCC  
hSGK1v2US CCCTCTGCCTTTCTGGCGCTGTTC 55 Will amplify human SGK1 variant 2 (NM_001143676.1) 
cDNA sequence of 140bp.  Also referred to as SGK1D. 
 
hSGK1v2DS CTGGAGGCGGCTTGAGAGAGGAG  
hSGK1v3US GAACAGGGATAGCCGTCTCTGGC 55 Will amplify human SGK1 variant31 (NM_001143677.1) 
cDNA sequence of 121bp.  Also referred to as SGK1C. 
 
hSGK1v3DS TTCTGGAGGCTGGAGGTAGAGCC  
hSGK1v4US AAAAGGCGTTTTCGGAAGCGACCC 55 Will amplify human SGK1 variant 4 (NM_001143678.1) 
cDNA sequence of 140bp.  Also referred to as SGK1B. 
 
hSGK1v4DS CAGACGAGAGCGACCGGCGAG  
hSGK1FUS TCTCCTCCTTCATCCACAGCTTTCA 55 Will amplify a novel human SGK1 variant (CAI19718) 
cDNA sequence of 211bp.  Also referred to as SGK1F. 
 
 
hSGK1FDS TGGACGACGGGCCAAGGTTG  
 
SGK1 Isoform 1 (NM_005627.3) is the wild type form SGK1A along with the 3 other forms 
identified by Simon et al37 -  isoform 2 (NM_001143676.1) is SGK1D; isoform 3 
(NM_001143677.1) is SGK1C and isoform 4 (NM_001143678.1) is SGK1B.  The SGK1F form 
sequence has been directly submitted to NCBI only - acc# CAI19718 and # FM205710. 
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